BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to analyze BK viral infection in salivary gland diseases;
specifically, to determine a definitive relationship between BK Virus and HIV associated
salivary gland disease (HIVSGD). Participants are adults HIV+SGD+ who will be randomized 1:1
to receive BK Virus antiviral (ciprofloxacin) or placebo for 28 days. Salivary
function/protein secretion will be correlated with BK polyomavirus titers. It is expected
that patients with HIV+SGD+ will have elevated oral BK polyomavirus viral loads and will
benefit from Ciprofloxacin.
Phase:
Phase 3
Details
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborator:
National Institute of Dental and Craniofacial Research (NIDCR)